Drug Profile
FT 011
Alternative Names: FT-011; SHP 627Latest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Fibrotech Therapeutics; University of Melbourne
- Developer Certa Therapeutics; OccuRx; Shire
- Class Alkynes; Anthranilic acids; Antifibrotics; Antiglaucomas; Caffeic acids; Heart failure therapies; Skin disorder therapies; Small molecules; Urologics
- Mechanism of Action GPR68 protein antagonists; Platelet-derived growth factor inhibitors; TGF-beta superfamily protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Focal segmental glomerulosclerosis; Systemic scleroderma
- Phase I Renal failure
- Discontinued Diabetic nephropathies; Glaucoma; Heart failure; Kidney disorders
Most Recent Events
- 19 Feb 2024 FT 011 receives Fast track status from the US FDA for Systemic scleroderma
- 23 Nov 2023 Discontinued - Phase-I for Glaucoma in Australia (PO) (Certa Therapeutics pipeline, November 2023)
- 23 Nov 2023 Discontinued - Phase-II for Diabetic nephropathies in Australia (PO) (Certa Therapeutics pipeline, November 2023)